Fibrinolytic Therapy for Refractory COVID‐19 Acute Respiratory Distress Syndrome: Scientific Rationale and Review
The COVID‐19 pandemic has caused respiratory failure and associated mortality in numbers that have overwhelmed global health systems. Thrombotic coagulopathy is present in nearly three‐quarters of COVID‐19 patients admitted to the intensive care unit, and both the clinical picture and pathologic fin...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Published: |
Wiley
2020
|
| Online Access: | https://hdl.handle.net/1721.1/125146 |
| _version_ | 1811074177331888128 |
|---|---|
| author | Barrett, Christopher D. Moore, Hunter B. Moore, Ernest E. McIntyre, Robert C. Moore, Peter K Burke, John Hua, Fei Apgar, Joshua Talmor, Daniel S. Sauaia, Angela Liptzin, Deborah R. Veress, Livia A. Yaffe, Michael B. |
| author2 | Koch Institute for Integrative Cancer Research at MIT |
| author_facet | Koch Institute for Integrative Cancer Research at MIT Barrett, Christopher D. Moore, Hunter B. Moore, Ernest E. McIntyre, Robert C. Moore, Peter K Burke, John Hua, Fei Apgar, Joshua Talmor, Daniel S. Sauaia, Angela Liptzin, Deborah R. Veress, Livia A. Yaffe, Michael B. |
| author_sort | Barrett, Christopher D. |
| collection | MIT |
| description | The COVID‐19 pandemic has caused respiratory failure and associated mortality in numbers that have overwhelmed global health systems. Thrombotic coagulopathy is present in nearly three‐quarters of COVID‐19 patients admitted to the intensive care unit, and both the clinical picture and pathologic findings are consistent with microvascular occlusive phenomena being a major contributor to their unique form of respiratory failure. Numerous studies are ongoing focusing on anti‐cytokine therapies, antibiotics and anti‐viral agents, but none to‐date have focused on treating the underlying thrombotic coagulopathy in an effort to improve respiratory failure in COVID‐19. There is animal data and a previous human trial demonstrating a survival advantage with fibrinolytic therapy to treat ARDS. Here we review the extant and emerging literature on the relationship between thrombotic coagulopathy and pulmonary failure in the context of COVID‐19 and present the scientific rationale for consideration of targeting the coagulation and fibrinolytic systems to improve pulmonary function in these patients. |
| first_indexed | 2024-09-23T09:44:39Z |
| format | Article |
| id | mit-1721.1/125146 |
| institution | Massachusetts Institute of Technology |
| last_indexed | 2024-09-23T09:44:39Z |
| publishDate | 2020 |
| publisher | Wiley |
| record_format | dspace |
| spelling | mit-1721.1/1251462022-09-30T16:34:39Z Fibrinolytic Therapy for Refractory COVID‐19 Acute Respiratory Distress Syndrome: Scientific Rationale and Review Barrett, Christopher D. Moore, Hunter B. Moore, Ernest E. McIntyre, Robert C. Moore, Peter K Burke, John Hua, Fei Apgar, Joshua Talmor, Daniel S. Sauaia, Angela Liptzin, Deborah R. Veress, Livia A. Yaffe, Michael B. Koch Institute for Integrative Cancer Research at MIT The COVID‐19 pandemic has caused respiratory failure and associated mortality in numbers that have overwhelmed global health systems. Thrombotic coagulopathy is present in nearly three‐quarters of COVID‐19 patients admitted to the intensive care unit, and both the clinical picture and pathologic findings are consistent with microvascular occlusive phenomena being a major contributor to their unique form of respiratory failure. Numerous studies are ongoing focusing on anti‐cytokine therapies, antibiotics and anti‐viral agents, but none to‐date have focused on treating the underlying thrombotic coagulopathy in an effort to improve respiratory failure in COVID‐19. There is animal data and a previous human trial demonstrating a survival advantage with fibrinolytic therapy to treat ARDS. Here we review the extant and emerging literature on the relationship between thrombotic coagulopathy and pulmonary failure in the context of COVID‐19 and present the scientific rationale for consideration of targeting the coagulation and fibrinolytic systems to improve pulmonary function in these patients. 2020-05-11T16:14:39Z 2020-05-11T16:14:39Z 2020-04 Article http://purl.org/eprint/type/JournalArticle 2475-0379 2475-0379 https://hdl.handle.net/1721.1/125146 Barrett, Christopher D. et al. "Fibrinolytic Therapy for Refractory COVID‐19 Acute Respiratory Distress Syndrome: Scientific Rationale and Review." Research and practice in thrombosis haemostatis (April 2020) http://dx.doi.org/10.1002/rth2.12357 Research and practice in thrombosis haemostatis Creative Commons Attribution-NonCommercial-NoDerivs License http://creativecommons.org/licenses/by-nc-nd/4.0/ application/pdf Wiley Wiley |
| spellingShingle | Barrett, Christopher D. Moore, Hunter B. Moore, Ernest E. McIntyre, Robert C. Moore, Peter K Burke, John Hua, Fei Apgar, Joshua Talmor, Daniel S. Sauaia, Angela Liptzin, Deborah R. Veress, Livia A. Yaffe, Michael B. Fibrinolytic Therapy for Refractory COVID‐19 Acute Respiratory Distress Syndrome: Scientific Rationale and Review |
| title | Fibrinolytic Therapy for Refractory COVID‐19 Acute Respiratory Distress Syndrome: Scientific Rationale and Review |
| title_full | Fibrinolytic Therapy for Refractory COVID‐19 Acute Respiratory Distress Syndrome: Scientific Rationale and Review |
| title_fullStr | Fibrinolytic Therapy for Refractory COVID‐19 Acute Respiratory Distress Syndrome: Scientific Rationale and Review |
| title_full_unstemmed | Fibrinolytic Therapy for Refractory COVID‐19 Acute Respiratory Distress Syndrome: Scientific Rationale and Review |
| title_short | Fibrinolytic Therapy for Refractory COVID‐19 Acute Respiratory Distress Syndrome: Scientific Rationale and Review |
| title_sort | fibrinolytic therapy for refractory covid 19 acute respiratory distress syndrome scientific rationale and review |
| url | https://hdl.handle.net/1721.1/125146 |
| work_keys_str_mv | AT barrettchristopherd fibrinolytictherapyforrefractorycovid19acuterespiratorydistresssyndromescientificrationaleandreview AT moorehunterb fibrinolytictherapyforrefractorycovid19acuterespiratorydistresssyndromescientificrationaleandreview AT mooreerneste fibrinolytictherapyforrefractorycovid19acuterespiratorydistresssyndromescientificrationaleandreview AT mcintyrerobertc fibrinolytictherapyforrefractorycovid19acuterespiratorydistresssyndromescientificrationaleandreview AT moorepeterk fibrinolytictherapyforrefractorycovid19acuterespiratorydistresssyndromescientificrationaleandreview AT burkejohn fibrinolytictherapyforrefractorycovid19acuterespiratorydistresssyndromescientificrationaleandreview AT huafei fibrinolytictherapyforrefractorycovid19acuterespiratorydistresssyndromescientificrationaleandreview AT apgarjoshua fibrinolytictherapyforrefractorycovid19acuterespiratorydistresssyndromescientificrationaleandreview AT talmordaniels fibrinolytictherapyforrefractorycovid19acuterespiratorydistresssyndromescientificrationaleandreview AT sauaiaangela fibrinolytictherapyforrefractorycovid19acuterespiratorydistresssyndromescientificrationaleandreview AT liptzindeborahr fibrinolytictherapyforrefractorycovid19acuterespiratorydistresssyndromescientificrationaleandreview AT veressliviaa fibrinolytictherapyforrefractorycovid19acuterespiratorydistresssyndromescientificrationaleandreview AT yaffemichaelb fibrinolytictherapyforrefractorycovid19acuterespiratorydistresssyndromescientificrationaleandreview |